ArticleJournal of controlled release : official journal of the Controlled Release Society2012
E-selectin liposomal and nanotube-targeted delivery of doxorubicin to circulating tumor cells.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 81 citations in OpenAlex.
- Personalized nanovaccines for treating solid cancer metastases.Journal of hematology & oncology · 2024Review
- Dual Affinity Nanoparticles for the Transport of Therapeutics from Carrier Cells to Target Cells under Physiological Flow Conditions.ACS omega · 2023Article
- Nanomedicine in cancer therapy.Signal transduction and targeted therapy · 2023Review
- Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy.Acta pharmaceutica Sinica. B · 2023Article
- Heterogeneity of Circulating Tumor Cells in Breast Cancer: Identifying Metastatic Seeds.International journal of molecular sciences · 2020Review
- Minimal dosing of leukocyte targeting TRAIL decreases triple-negative breast cancer metastasis following tumor resection.Science advances · 2019Article
- Delivery technologies for cancer immunotherapy.Nature reviews. Drug discovery · 2019Review
- Is small smarter? Nanomaterial-based detection and elimination of circulating tumor cells: current knowledge and perspectives.International journal of nanomedicine · 2019Review
- Nanovesicle-mediated delivery of anticancer agents effectively induced cell death and regressed intrahepatic tumors in athymic mice.Laboratory investigation; a journal of technical methods and pathology · 2018Article
- RNA interference-based therapy and its delivery systems.Cancer metastasis reviews · 2018Review
- Review
- Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior.Advanced drug delivery reviews · 2017Review
- Nanomaterials for the Capture and Therapeutic Targeting of Circulating Tumor Cells.Cellular and molecular bioengineering · 2017Review
- DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2016Article
- Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.Nanomedicine : nanotechnology, biology, and medicine · 2016Review
- Bauhinia purprea agglutinin-modified liposomes for human prostate cancer treatment.Cancer science · 2016Article
- Lamin A/C deficiency reduces circulating tumor cell resistance to fluid shear stress.American journal of physiology. Cell physiology · 2015Article
- Immobilized surfactant-nanotube complexes support selectin-mediated capture of viable circulating tumor cells in the absence of capture antibodies.Journal of biomedical materials research. Part A · 2015Article
- Surfactant functionalization induces robust, differential adhesion of tumor cells and blood cells to charged nanotube-coated biomaterials under flow.Biomaterials · 2015Article
- Leukocytes as carriers for targeted cancer drug delivery.Expert opinion on drug delivery · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The presence of circulating tumor cells (CTCs) is believed to lead to the formation of secondary tumors via an adhesion cascade involving interaction between adhesion receptors of endothelial cells and ligands on CTCs. Many CTCs express sialylated carbohydrate ligands on their surfaces that adhere to selectin protein found on inflamed endothelial cells. We have investigated the feasibility of using immobilized selectin proteins as a targeting mechanism for CTCs under flow. Herein, targeted liposomal doxorubicin (L-DXR) was functionalized with recombinant human E-selectin (ES) and polyethylene glycol (PEG) to target and kill cancer cells under shear flow, both when immobilized along a microtube device or sheared in a cone-and-plate viscometer in a dilute suspension. Healthy circulating cells such as red blood cells were not targeted by this mechanism and were left to freely circulate, and minimal leukocyte death was observed. Halloysite nanotube (HNT)-coated microtube devices immobilized with nanoscale liposomes significantly enhanced the targeting, capture, and killing of cancer cells. This work demonstrates that E-selectin functionalized L-DXR, sheared in suspension or immobilized onto microtube devices, provides a novel approach to selectively target and deliver chemotherapeutics to CTCs in the bloodstream.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.